Browsing Clinical Studies by author "Lee, Alexander"

Now showing items 1-8 of 8

    • 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. 

      Frezza, AM; Lee, ATJ; Nizri, E; Sbaraglia, M; Jones, RL; et al. (ELSEVIER, 2018-05-01)
      The 7th edition of the 'ESMO Sarcoma and GIST Symposium' was held in Milan in February 2018. For the first time, the Symposium brought together representatives from the European Reference Network on rare adult solid cancer ...

    • Clinical and Molecular Spectrum of Liposarcoma. 

      Lee, ATJ; Thway, K; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2018-01-10)
      Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ...

    • Drug repositioning in sarcomas and other rare tumors. 

      Lee, ATJ; Huang, PH; Pollack, SM; Jones, RL (ELSEVIER SCIENCE BV, 2016-03-17)

    • Novel therapeutic approaches in chondrosarcoma. 

      Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; et al. (FUTURE MEDICINE LTD, 2017-03-01)
      Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ...

    • Olaratumab in soft tissue sarcoma - Current status and future perspectives. 

      Antoniou, G; Lee, ATJ; Huang, PH; Jones, RL (ELSEVIER SCI LTD, 2018-03-01)
      Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ...

    • Pazopanib in advanced soft tissue sarcomas. 

      Lee, ATJ; Jones, RL; Huang, PH (NATURE PUBLISHING GROUP, 2019-05-17)
      Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...

    • Phase III Soft Tissue Sarcoma Trials: Success or Failure? 

      Lee, ATJ; Pollack, SM; Huang, P; Jones, RL (SPRINGER, 2017-03-01)
      Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II ...

    • The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. 

      Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; et al. (NATURE PORTFOLIO, 2019-10-10)
      The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ...